Compass Pathways took a 50% on June 23 hit after a lukewarm trial, but long-term bulls see upside in psychedelics.

Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and ...

Compass Pathways' COMP005 trial met its primary endpoint in TRD, but modest results sparked a 47% drop in shares amid ...

Compass Pathways’ stock has crashed by nearly 50% despite the company announcing its Phase III trial of psilocybin had met ...

Stifel said the plunge in Compass Pathways shares was “significantly overdone” after data showed that the company’s COMP360 met the primary endpoint in a Phase 3 trial for treatment-resistant ...

Though caution is required when the data haven't been published, it could be a landmark in the drug's journey toward FDA ...

Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity ...

Compass Pathways' Phase 3 COMP-360 data met primary endpoints but disappointed vs analyst expectations. See why investors ...

Findings showed COMP360 psilocybin statistically significantly reduced symptom severity compared with placebo, as measured by MADRS.

Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called ...

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in ...

Compass Pathways’ depression drug trial meets goals but falls short of investor hopes, triggering a sharp share selloff.